Fast Five Quiz: Advanced and Metastatic Breast Cancer Myths

Pavani Chalasani, MD, MPH; Stefania Morganti, MD


April 20, 2023

The Endocrine Society guidelines on hormonal replacement in postmenopausal women advise that the underlying individual risk for breast cancer must be considered. Nonhormonal therapies are recommended for women at high or intermediate risk for breast cancer who are considering hormone therapy to alleviate severe vasomotor symptoms associated with menopause. The same guidelines recommend against the use of tibolone in women with a history of breast cancer.

HRT containing both estrogen and progestin is associated with the highest risk for heart disease and breast cancer, whereas the degree of risk appears to be lower for women who take estrogen alone. The effect of HRT on breast cancer risk also depends on the individual risk of developing breast cancer.

Learn more about menopausal HRT.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.